Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS8 | Q16651 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 14/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | PTPRB | P23467 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062946 | 1.00 | PRSS8 (0.40) | PRSS8CTSSCTSLCTSBCTSK | |
| SCHEMBL6464673 | 0.92 | PRSS8 (0.40) | PRSS8CTSSCTSLCTSBCTSK | |
| SCHEMBL6467209 | 0.88 | PRSS8 (0.39) | PRSS8CTSSCTSLCTSBCTSK | |
| SCHEMBL6061657 | 0.84 | PRSS8 (0.43) | PRSS8CTSSCTSLCTSBCTSK | |
| SCHEMBL6062953 | 0.83 | CTSS (0.43) | PRSS8CTSSCTSLCTSBCTSK | |
| SCHEMBL7047995 | 0.82 | CTSS (0.46) | PRSS8CTSSCTSLCTSBCTSK | |
| SCHEMBL7048381 | 0.79 | PRSS8 (0.38) | PRSS8CTSSCTSLCTSBCTSK | |
| SCHEMBL7049413 | 0.77 | CTSL (0.41) | PRSS8CTSSCTSLCTSBCTSK | |
| SCHEMBL7183810 | 0.76 | CTSL (0.42) | PRSS8CTSSCTSLCTSBCTSK | |
| SCHEMBL7044250 | 0.76 | PRSS8 (0.47) | PRSS8CTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694357-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058348-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | PRSS8 33/4885CTSS 9/4885CTSL 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.